Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)

PURPOSE: To explore the efficacy of retreatment with immune checkpoint inhibitors (ICI) in patients with advanced non–small cell lung cancer (NSCLC) who responded to prior ICI and had adequate ICI-free interval. PATIENTS AND METHODS: Patients with advanced NSCLC who had achieved complete response (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Akamatsu, Hiroaki, Teraoka, Shunsuke, Takamori, Shinkichi, Miura, Satoru, Hayashi, Hidetoshi, Hata, Akito, Toi, Yukihiro, Shiraishi, Yoshimasa, Mamesaya, Nobuaki, Sato, Yuki, Furuya, Naoki, Oyanagi, Jun, Koh, Yasuhiro, Misumi, Toshihiro, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Briefs: Clinical Trial Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662947/
https://www.ncbi.nlm.nih.gov/pubmed/35762926
http://dx.doi.org/10.1158/1078-0432.CCR-22-0602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662947/
https://www.ncbi.nlm.nih.gov/pubmed/35762926
http://dx.doi.org/10.1158/1078-0432.CCR-22-0602

Ejemplares similares